Does the media refer more to VRDN or NGNE?

In the previous week, Viridian Therapeutics had 2 more articles in the media than Neurogene. MarketBeat recorded 5 mentions for Viridian Therapeutics and 3 mentions for Neurogene. Neurogene's average media sentiment score of 0.50 beat Viridian Therapeutics' score of 0.45 indicating that Neurogene is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viridian Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Neurogene 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, ADMA or NGNE?

ADMA Biologics has higher revenue and earnings than Neurogene. Neurogene is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ADMA Biologics $510.17M 4.27 $146.93M $0.70 13.89 Neurogene $930K 551.89 -$90.35M -$5.03 N/A

Is ADMA or NGNE more profitable?

ADMA Biologics has a net margin of 32.98% compared to Neurogene's net margin of 0.00%. ADMA Biologics' return on equity of 40.17% beat Neurogene's return on equity. Company Net Margins Return on Equity Return on Assets ADMA Biologics 32.98% 40.17% 26.97% Neurogene N/A -45.10% -41.00%

Does the media prefer ADMA or NGNE?

In the previous week, ADMA Biologics and ADMA Biologics both had 3 articles in the media. Neurogene's average media sentiment score of 0.50 beat ADMA Biologics' score of 0.27 indicating that Neurogene is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Neurogene 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer NGNE or AUPH?

In the previous week, Aurinia Pharmaceuticals had 1 more articles in the media than Neurogene. MarketBeat recorded 4 mentions for Aurinia Pharmaceuticals and 3 mentions for Neurogene. Aurinia Pharmaceuticals' average media sentiment score of 0.69 beat Neurogene's score of 0.50 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurogene 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aurinia Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to BCRX or NGNE?

In the previous week, BioCryst Pharmaceuticals and BioCryst Pharmaceuticals both had 3 articles in the media. Neurogene's average media sentiment score of 0.50 beat BioCryst Pharmaceuticals' score of 0.31 indicating that Neurogene is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCryst Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Neurogene 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, PHVS or NGNE?

Neurogene has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than Neurogene, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pharvaris N/A N/A -$198.79M -$3.05 N/A Neurogene $930K 551.89 -$90.35M -$5.03 N/A

Is PHVS or NGNE more profitable?

Neurogene's return on equity of -45.10% beat Pharvaris' return on equity. Company Net Margins Return on Equity Return on Assets Pharvaris N/A -61.40% -56.00% Neurogene N/A -45.10% -41.00%

Does the media refer more to PHVS or NGNE?

In the previous week, Pharvaris and Pharvaris both had 3 articles in the media. Pharvaris' average media sentiment score of 0.68 beat Neurogene's score of 0.50 indicating that Pharvaris is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharvaris 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neurogene 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Neurogene (NGNE) Competitors

$25.65 -0.90 (-3.39%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$25.62 -0.04 (-0.14%)

As of 10/2/2026 07:30 PM Eastern

Compare

NGNE vs. VRDN, ADMA, AUPH, BCRX, and PHVS

Should you buy Neurogene stock or one of its competitors? Neurogene's main competitors and comparable companies include Viridian Therapeutics (VRDN), ADMA Biologics (ADMA), Aurinia Pharmaceuticals (AUPH), BioCryst Pharmaceuticals (BCRX), and Pharvaris (PHVS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Neurogene compare to Viridian Therapeutics?

Viridian Therapeutics (NASDAQ:VRDN) and Neurogene (NASDAQ:NGNE) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, media sentiment, risk, analyst recommendations, profitability and institutional ownership.

Neurogene has a net margin of 0.00% compared to Viridian Therapeutics' net margin of -505.86%. Neurogene's return on equity of -45.10% beat Viridian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viridian Therapeutics	-505.86%	-72.97%	-42.80%
Neurogene	N/A	-45.10%	-41.00%

52.4% of Neurogene shares are owned by institutional investors. 2.4% of Viridian Therapeutics shares are owned by company insiders. Comparatively, 11.7% of Neurogene shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Viridian Therapeutics has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market. Comparatively, Neurogene has a beta of 1.7, suggesting that its stock price is 70% more volatile than the broader market.

Viridian Therapeutics presently has a consensus price target of $38.69, suggesting a potential upside of 99.44%. Neurogene has a consensus price target of $83.67, suggesting a potential upside of 226.19%. Given Neurogene's stronger consensus rating and higher probable upside, analysts clearly believe Neurogene is more favorable than Viridian Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viridian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Neurogene	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

Neurogene has lower revenue, but higher earnings than Viridian Therapeutics. Viridian Therapeutics is trading at a lower price-to-earnings ratio than Neurogene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viridian Therapeutics	$70.85M	31.02	-$342.60M	-$3.37	N/A
Neurogene	$930K	551.89	-$90.35M	-$5.03	N/A

In the previous week, Viridian Therapeutics had 2 more articles in the media than Neurogene. MarketBeat recorded 5 mentions for Viridian Therapeutics and 3 mentions for Neurogene. Neurogene's average media sentiment score of 0.50 beat Viridian Therapeutics' score of 0.45 indicating that Neurogene is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viridian Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Neurogene	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Neurogene beats Viridian Therapeutics on 13 of the 17 factors compared between the two stocks.

How does Neurogene compare to ADMA Biologics?

ADMA Biologics (NASDAQ:ADMA) and Neurogene (NASDAQ:NGNE) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

ADMA Biologics has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market. Comparatively, Neurogene has a beta of 1.7, suggesting that its stock price is 70% more volatile than the broader market.

ADMA Biologics has higher revenue and earnings than Neurogene. Neurogene is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$510.17M	4.27	$146.93M	$0.70	13.89
Neurogene	$930K	551.89	-$90.35M	-$5.03	N/A

ADMA Biologics currently has a consensus target price of $18.67, suggesting a potential upside of 92.04%. Neurogene has a consensus target price of $83.67, suggesting a potential upside of 226.19%. Given Neurogene's stronger consensus rating and higher possible upside, analysts plainly believe Neurogene is more favorable than ADMA Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Neurogene	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, ADMA Biologics and ADMA Biologics both had 3 articles in the media. Neurogene's average media sentiment score of 0.50 beat ADMA Biologics' score of 0.27 indicating that Neurogene is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Neurogene	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ADMA Biologics has a net margin of 32.98% compared to Neurogene's net margin of 0.00%. ADMA Biologics' return on equity of 40.17% beat Neurogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	32.98%	40.17%	26.97%
Neurogene	N/A	-45.10%	-41.00%

75.7% of ADMA Biologics shares are held by institutional investors. Comparatively, 52.4% of Neurogene shares are held by institutional investors. 3.9% of ADMA Biologics shares are held by insiders. Comparatively, 11.7% of Neurogene shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

ADMA Biologics and Neurogene tied by winning 8 of the 16 factors compared between the two stocks.

How does Neurogene compare to Aurinia Pharmaceuticals?

Neurogene (NASDAQ:NGNE) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment.

Aurinia Pharmaceuticals has higher revenue and earnings than Neurogene. Neurogene is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurogene	$930K	551.89	-$90.35M	-$5.03	N/A
Aurinia Pharmaceuticals	$283.05M	7.44	$287.20M	$2.29	6.91

In the previous week, Aurinia Pharmaceuticals had 1 more articles in the media than Neurogene. MarketBeat recorded 4 mentions for Aurinia Pharmaceuticals and 3 mentions for Neurogene. Aurinia Pharmaceuticals' average media sentiment score of 0.69 beat Neurogene's score of 0.50 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurogene	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aurinia Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Neurogene has a beta of 1.7, indicating that its stock price is 70% more volatile than the broader market. Comparatively, Aurinia Pharmaceuticals has a beta of 1.6, indicating that its stock price is 60% more volatile than the broader market.

Aurinia Pharmaceuticals has a net margin of 100.84% compared to Neurogene's net margin of 0.00%. Aurinia Pharmaceuticals' return on equity of 26.11% beat Neurogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurogene	N/A	-45.10%	-41.00%
Aurinia Pharmaceuticals	100.84%	26.11%	19.89%

52.4% of Neurogene shares are owned by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. 11.7% of Neurogene shares are owned by insiders. Comparatively, 10.4% of Aurinia Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Neurogene currently has a consensus price target of $83.67, indicating a potential upside of 226.19%. Aurinia Pharmaceuticals has a consensus price target of $17.67, indicating a potential upside of 11.60%. Given Neurogene's stronger consensus rating and higher probable upside, research analysts plainly believe Neurogene is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurogene	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Aurinia Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

Aurinia Pharmaceuticals beats Neurogene on 9 of the 17 factors compared between the two stocks.

How does Neurogene compare to BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Neurogene (NASDAQ:NGNE) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and institutional ownership.

BioCryst Pharmaceuticals presently has a consensus target price of $20.50, suggesting a potential upside of 150.92%. Neurogene has a consensus target price of $83.67, suggesting a potential upside of 226.19%. Given Neurogene's stronger consensus rating and higher probable upside, analysts clearly believe Neurogene is more favorable than BioCryst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Neurogene	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, BioCryst Pharmaceuticals and BioCryst Pharmaceuticals both had 3 articles in the media. Neurogene's average media sentiment score of 0.50 beat BioCryst Pharmaceuticals' score of 0.31 indicating that Neurogene is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCryst Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Neurogene	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 52.4% of Neurogene shares are held by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are held by insiders. Comparatively, 11.7% of Neurogene shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Neurogene has a net margin of 0.00% compared to BioCryst Pharmaceuticals' net margin of -40.90%. Neurogene's return on equity of -45.10% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-40.90%	-86.89%	66.37%
Neurogene	N/A	-45.10%	-41.00%

BioCryst Pharmaceuticals has higher revenue and earnings than Neurogene. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Neurogene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$874.84M	2.39	$263.86M	-$1.50	N/A
Neurogene	$930K	551.89	-$90.35M	-$5.03	N/A

BioCryst Pharmaceuticals has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market. Comparatively, Neurogene has a beta of 1.7, meaning that its share price is 70% more volatile than the broader market.

Summary

Neurogene beats BioCryst Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Neurogene compare to Pharvaris?

Pharvaris (NASDAQ:PHVS) and Neurogene (NASDAQ:NGNE) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

Pharvaris has a beta of -2.46, indicating that its stock price is 346% less volatile than the broader market. Comparatively, Neurogene has a beta of 1.7, indicating that its stock price is 70% more volatile than the broader market.

In the previous week, Pharvaris and Pharvaris both had 3 articles in the media. Pharvaris' average media sentiment score of 0.68 beat Neurogene's score of 0.50 indicating that Pharvaris is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharvaris	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neurogene	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Neurogene has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than Neurogene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharvaris	N/A	N/A	-$198.79M	-$3.05	N/A
Neurogene	$930K	551.89	-$90.35M	-$5.03	N/A

Neurogene's return on equity of -45.10% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharvaris	N/A	-61.40%	-56.00%
Neurogene	N/A	-45.10%	-41.00%

Pharvaris presently has a consensus target price of $59.87, suggesting a potential upside of 91.94%. Neurogene has a consensus target price of $83.67, suggesting a potential upside of 226.19%. Given Neurogene's stronger consensus rating and higher possible upside, analysts plainly believe Neurogene is more favorable than Pharvaris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharvaris	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Neurogene	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

52.4% of Neurogene shares are owned by institutional investors. 11.8% of Pharvaris shares are owned by insiders. Comparatively, 11.7% of Neurogene shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Neurogene beats Pharvaris on 10 of the 14 factors compared between the two stocks.

Get Neurogene News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NGNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NGNE vs. The Competition

Export

Metric	Neurogene	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$513.28M	$3.86B	$7.15B	$13.28B
Dividend Yield	N/A	3.65%	2.54%	17.33%
P/E Ratio	-5.10	13.06	275.67	26.04
Price / Sales	551.89	1,292.17	656.66	111.05
Price / Cash	N/A	123.39	78.87	52.62
Price / Book	1.50	16.63	10.93	6.31
Net Income	-$90.35M	-$22.71M	$3.51B	$362.16M
7 Day Performance	-9.40%	-2.99%	-2.00%	-1.66%
1 Month Performance	-33.55%	-10.81%	-6.19%	-4.68%
1 Year Performance	14.82%	19.19%	8.03%	1.57%

Neurogene Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NGNE Neurogene	2.8011 of 5 stars	$25.65 -3.4%	$83.67 +226.2%	+14.8%	$513.28M	$930K	N/A	131	News Coverage
VRDN Viridian Therapeutics	2.5325 of 5 stars	$19.82 -3.7%	$38.69 +95.3%	-10.4%	$2.25B	$70.85M	N/A	252	News Coverage Analyst Downgrade
ADMA ADMA Biologics	3.2316 of 5 stars	$9.99 -1.3%	$18.67 +86.9%	-33.7%	$2.24B	$510.17M	14.31	647
AUPH Aurinia Pharmaceuticals	3.6244 of 5 stars	$16.28 -1.4%	$17.67 +8.5%	+39.5%	$2.16B	$283.05M	7.11	128
BCRX BioCryst Pharmaceuticals	2.3461 of 5 stars	$8.39 -1.0%	$20.40 +143.3%	+14.3%	$2.14B	$874.84M	N/A	435	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NGNE) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Neurogene (NGNE) Competitors

NGNE vs. VRDN, ADMA, AUPH, BCRX, and PHVS

How does Neurogene compare to Viridian Therapeutics?

Summary

How does Neurogene compare to ADMA Biologics?

Summary

How does Neurogene compare to Aurinia Pharmaceuticals?

Summary

How does Neurogene compare to BioCryst Pharmaceuticals?

Summary

How does Neurogene compare to Pharvaris?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NGNE vs. The Competition

Neurogene Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Neurogene (NGNE) Competitors

NGNE vs. VRDN, ADMA, AUPH, BCRX, and PHVS

How does Neurogene compare to Viridian Therapeutics?

Is VRDN or NGNE more profitable?

Do insiders & institutionals hold more shares of VRDN or NGNE?

Which has more risk and volatility, VRDN or NGNE?

Do analysts recommend VRDN or NGNE?

Which has higher earnings & valuation, VRDN or NGNE?

Does the media refer more to VRDN or NGNE?

Summary

How does Neurogene compare to ADMA Biologics?

Which has more volatility & risk, ADMA or NGNE?

Which has stronger valuation and earnings, ADMA or NGNE?

Do analysts rate ADMA or NGNE?

Does the media prefer ADMA or NGNE?

Is ADMA or NGNE more profitable?

Do institutionals and insiders hold more shares of ADMA or NGNE?

Summary

How does Neurogene compare to Aurinia Pharmaceuticals?

Which has higher valuation and earnings, NGNE or AUPH?

Does the media prefer NGNE or AUPH?

Which has more volatility & risk, NGNE or AUPH?

Is NGNE or AUPH more profitable?

Do institutionals & insiders believe in NGNE or AUPH?

Do analysts prefer NGNE or AUPH?

Summary

How does Neurogene compare to BioCryst Pharmaceuticals?

Do analysts rate BCRX or NGNE?

Does the media refer more to BCRX or NGNE?

Do institutionals and insiders hold more shares of BCRX or NGNE?

Is BCRX or NGNE more profitable?

Which has stronger valuation & earnings, BCRX or NGNE?

Which has more risk & volatility, BCRX or NGNE?

Summary

How does Neurogene compare to Pharvaris?

Which has more volatility and risk, PHVS or NGNE?

Does the media refer more to PHVS or NGNE?

Which has preferable valuation and earnings, PHVS or NGNE?

Is PHVS or NGNE more profitable?

Do analysts recommend PHVS or NGNE?

Do insiders & institutionals hold more shares of PHVS or NGNE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NGNE vs. The Competition

Neurogene Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools